New drug cocktail aims to shrink lung tumors before surgery

NCT ID NCT07089199

Recruiting now Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery to people with stage III non-small cell lung cancer. The goal is to see if this approach can eliminate or greatly reduce the tumor before it is removed. The study plans to enroll 34 participants and will also monitor side effects and long-term outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tislelizumab, anlotinib, and nab-paclitaxel
What this could lead to: If successful, this could lead to a new treatment approach to shrink tumors before surgery and improve outcomes for people with stage III non-small cell lung cancer.
What could go wrong: This is a small, early-phase trial with only 34 participants and no comparison group. The combination may cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANLOTINIB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANLOTINIB NAB-PACLITAXEL NSCLC TISLELIZUMAB

Contacts and locations

Locations

Qilu Hospital of Shandong University
RECRUITING

Jinan, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.